Month: April 2021

ASi Tallinna Sadam (edaspidi „Tallinna Sadam“) nõukogu kiitis heaks juhatuse poolt esitatud 2020. a auditeeritud majandusaasta aruande. 2020. a finantstulemused ei ole muutunud võrreldes 26.02.2021 avaldatud 12-kuu auditeerimata majandustulemustega. Eelmisel aastal moodustas Tallinna Sadama grupi müügitulu 107,4 mln eurot (–17,8%) ja korrigeeritud EBITDA 58,4 miljonit eurot (–21,4%). Pandeemia mõjude tõttu kujunes 2020. aasta kasumiks 28,5 mln eurot (–35,8%). Korrigeeritud EBITDA marginaal vähenes 2,5 protsendipunkti võrra, kuid investeeringute maht kasvas 37,1 mln euroni (26%). Tallinna Sadama juhatuse esimehe Valdo Kalmu sõnul oli pandeemia negatiivne mõju ettevõtte majandustulemustele eriti tuntav reisisadamate segmendis, kuid tervikvaates oli viiruse mõju kontserni finantsidele kardetust väiksem ning aasta lõpetati olusid arvestades...

NORWALK, Conn. and TOKYO, April 05, 2021 (GLOBE NEWSWIRE) — 東京証券取引所（以下「東証」）とFactSetは、今般、日本株を対象とするテーマ型指数「JPX/FactSet　テーマ型指数シリーズ」の試験算出を開始することといたしました。日本を代表する株価指数である「東証株価指数（TOPIX）」等の株価指数を算出する東証と、グローバルな金融データ・テクノロジー企業として業界をリードするコンテンツや分析ソリューションを投資家に提供するFactSetの両者の強みをいかし、新たな株価指数の開発を進めます。 第一弾では、「人生100年」、「地方関連」及び「ASEAN地域」の3つのテーマに基づく株価指数のプロトタイプを開発し、今後、マーケティングを開始いたします。JPX/FactSet人生100年関連指数：我が国の高齢化が加速する中、いわゆる健康寿命の延伸などに対応した事業が注目されています。本指数は、高齢化が進む社会を支える技術やサービスを提供していると考えられる企業を構成銘柄として算出するものです。具体的には、FactSet独自業種分類であるRevere Business Industry Classification System（RBICS）の、「ヘルスケア・医療技術」、「レジャー」、「フィットネス・美容」、「ウェルスマネジメント」の4テーマに着目し、これに該当する東証上場の企業・REITにより構成されています。JPX/FactSet地方関連指数：社会環境の変化に対応し、東京圏以外の地域における事業・サービスへの関心が高まっています。本指数は、一都三県（東京都、千葉県、神奈川県、埼玉県）外に本社が所在し、FactSet独自のデータセットであるGeographic Revenue Exposure（GeoRev）、Supply Chain Relationships、FactSet Fundamentalsを基に、国内での売上高が50％以上かつ、一都三県以外の売上高比率の高い企業を構成銘柄として算出するものです。JPX/FactSet...

HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipment Reaffirms 2021 financial guidanceGAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS). The $23 million will be used for the purchase of biologics manufacturing...

Steve Muehler stated, “when the whole Regulation A+ thing started, we were at the forefront of the industry, part of the groups blazing new trails. With the World now starting to move faster and faster towards Block Chain Trading Systems and Digital Currencies, and that whole industry landscape changing and evolving at such a rapid speed, it was prudent to preserve what was accomplished and continue our own evolution. But our evolution is not in the speculative markets of Digital Currencies or as a Block Chain technologies provider. Though Digital Currencies are our future, the marketplace for them today is far to oversaturated for us to pick a team, and we are on the outside looking in at the new breed of industry pioneer and trail blazers. For us today discretion is the better part of valor, and Steve Muehler Holdings is steadfast focused...

[Press release] QuipuSwap, the first Uniswap-like DEX on Tezos, launches on the mainnet The Madfish team has announced the QuipuSwap DEX launch.This open-source AMM protocol provides an interface for the seamless exchange of Tezos-based tokens and XTZ. In other words, you may add or trade any FA1.2 or FA2 standard tokens without limitations.Check it out at https://quipuswap.com/swap. QuipuSwap stands to be the main entry point for new DeFi projects accelerating the Tezos ecosystem’s development. QuipuSwap is driven by security, decentralization, and scalability principles. It serves as a standalone project, and at the same time, as an indispensable tool for the future DeFi solutions developed on the Tezos blockchain. The external security audit was conducted by LeastAuthority, the company that published audit reports for Ethereum,...

Termination of the business combination withSecond Sight Medical Products, Inc. Paris, France, April 3, 2021 – Considering the private placement recently announced and closed by Second Sight Medical Products, Inc. (“Second Sight”) was not only explicitly prohibited under the terms of the memorandum of understanding (“MOU”) entered into by the companies on January 5, 20211 but also detrimental to Pixium Vision’s interests, the company has offered Second Sight to renegotiate the MOU in order to allow the pursuit of the business combination while preserving the contractual balance and the interests of Pixium Vision and its shareholders. Pixium Vision regrets that Second Sight never responded to the proposals it made in good faith nor demonstrated any willingness to reach such agreement. Following this delaying attitude and refusal to enter...

Abandon du rapprochement avecSecond Sight Medical Products, Inc. Paris, France, 3 avril 2021 – Compte-tenu de l’augmentation de capital réalisée récemment par Second Sight Medical Products, Inc. (« Second Sight ») en violation du protocole d’accord conclu le 5 janvier 20211 et qui porte atteinte aux intérêts de Pixium Vision, cette dernière a proposé à Second Sight de renégocier le protocole d’accord afin de permettre la poursuite du projet rapprochement tout en préservant l’équilibre contractuel initial ainsi que les intérêts de Pixium Vision et de ses actionnaires. Pixium Vision regrette que Second Sight n’ait jamais répondu aux propositions qu’elle a faites, de bonne foi, ni démontré une quelconque volonté de parvenir à un tel accord. Persévérant dans une attitude dilatoire et refusant d’entamer des discussions avec la société, Second...

Termination of the business combination withSecond Sight Medical Products, Inc. Paris, France, April 3, 2021 – Considering the private placement recently announced and closed by Second Sight Medical Products, Inc. (“Second Sight”) was not only explicitly prohibited under the terms of the memorandum of understanding (“MOU”) entered into by the companies on January 5, 20211 but also detrimental to Pixium Vision’s interests, the company has offered Second Sight to renegotiate the MOU in order to allow the pursuit of the business combination while preserving the contractual balance and the interests of Pixium Vision and its shareholders. Pixium Vision regrets that Second Sight never responded to the proposals it made in good faith nor demonstrated any willingness to reach such agreement. Following this delaying attitude and refusal to enter...

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age. “Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD,” said Jack A. Khattar, President and Chief Executive...